DRG Market Assessment reports

Clarivate’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key thyroid cancer patient populations covering 171 countries and more than…

Clarivate Epidemiology’s coverage of cholangiocarcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key cholangiocarcinoma patient populations, covering 171 countries and…

Clarivate Epidemiology’s coverage of cholangiocarcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of graft versus host disease (GVHD) comprises epidemiological estimates of key patient populations in the emerging pharmaceutical markets (Brazil, China, India,…

Clarivate Epidemiology’s coverage of graft versus host disease (GVHD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…

Clarivate Epidemiology’s coverage of alopecia areata (AA) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France,…

Clarivate Epidemiology’s coverage of phenylketonuria comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…

Clarivate Epidemiology’s coverage of ocular pain comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy…

Clarivate Epidemiology’s coverage of Stargardt disease (STGD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…

Clarivate Epidemiology’s coverage of Hodgkin’s lymphoma (HL) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…

Clarivate Epidemiology’s coverage of NK / T-cell lymphoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence…